Kin Li - Sihuan Pharmaceutical Joint Sec

All Insiders . USA . 
Stock . Sihuan Pharmaceutical Holdings . Stakeholders . Insider . Kin Li
SHPHF Stock  USD 0.17  0.00  0.00%   

Insider

Kin Li is Joint Sec of Sihuan Pharmaceutical Holdings
Age 35
Phone852 3628 3911
Webhttps://www.sihuanpharm.com

Sihuan Pharmaceutical Management Efficiency

Sihuan Pharmaceutical's management efficiency ratios could be used to measure how well Sihuan Pharmaceutical manages its routine affairs as well as how well it operates its assets and liabilities.
Sihuan Pharmaceutical Holdings has accumulated 844.75 M in total debt with debt to equity ratio (D/E) of 0.14, which may suggest the company is not taking enough advantage from borrowing. Sihuan Pharmaceutical has a current ratio of 2.38, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Sihuan Pharmaceutical until it has trouble settling it off, either with new capital or with free cash flow. So, Sihuan Pharmaceutical's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Sihuan Pharmaceutical sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Sihuan to invest in growth at high rates of return. When we think about Sihuan Pharmaceutical's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Selina ZhangHUTCHMED Limited
N/A
ACGI BScHUTCHMED Limited
70
Hong ChenHUTCHMED Limited
53
Xi LuoCanSino Biologics
46
Karen BergFagron NV
N/A
Joe HollandCuraleaf Holdings
N/A
Andrew PulidoFagron NV
N/A
James ShorrisCuraleaf Holdings
61
Lorraine HillAspen Pharmacare Holdings
59
Christof DreibholzDermapharm Holding SE
56
Peter JDCuraleaf Holdings
55
Qingmei WangHUTCHMED Limited
60
Charles NixonHUTCHMED Limited
53
Karl ZiegelbauerAlmirall SA
N/A
Dongxu MBACanSino Biologics
62
FCS FCISCanSino Biologics
46
Jing WangCanSino Biologics
42
Matthew DarinCuraleaf Holdings
N/A
Edward KremerCuraleaf Holdings
51
Stavros NicolaouAspen Pharmacare Holdings
58
Chunlin XinCanSino Biologics
N/A
Sihuan Pharmaceutical Holdings Group Ltd., an investment holding company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in the Peoples Republic of China. The company was founded in 2001 and is based in Wanchai, Hong Kong. Sihuan Pharmaceutical operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange. It employs 3896 people. Sihuan Pharmaceutical Holdings [SHPHF] is a Pink Sheet which is traded between brokers as part of OTC trading.

Management Performance

Return On Equity-0.0487
Return On Asset-4.0E-4

Sihuan Pharmaceutical Leadership Team

Elected by the shareholders, the Sihuan Pharmaceutical's board of directors comprises two types of representatives: Sihuan Pharmaceutical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Sihuan. The board's role is to monitor Sihuan Pharmaceutical's management team and ensure that shareholders' interests are well served. Sihuan Pharmaceutical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Sihuan Pharmaceutical's outside directors are responsible for providing unbiased perspectives on the board's policies.
Weicheng Guo, Deputy Chairman, CEO and Member of Nomination Committee
Xianhui Meng, Deputy General Manager of Sales and Marketing and Executive Director
Yanling Chen, Joint Director
Guili Miao, Chief CEO
Kin Li, Joint Sec
Fengsheng Che, Co-Founder, Executive Chairman and Member of Remuneration Committee
Jionglong Zhang, Non-Executive Director
Chengkon Shih, General Manager of Shandong Xuanzhu
Feng Guo, Executive Director

Sihuan Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Sihuan Pharmaceutical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity-0.0487
Return On Asset-4.0E-4
Profit Margin(0.05) %
Operating Margin(0) %
Current Valuation506.36 M
Shares Outstanding9.33 B
Shares Owned By Insiders55.02 %
Shares Owned By Institutions4.21 %
Price To Earning8.75 X
Price To Book0.81 X

Currently Active Assets on Macroaxis

HITIHigh Tide
HITIHigh Tide
BACBank of America
SSentinelOne
GMGeneral Motors

Other Information on Investing in Sihuan Pink Sheet

Sihuan Pharmaceutical financial ratios help investors to determine whether Sihuan Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Sihuan with respect to the benefits of owning Sihuan Pharmaceutical security.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY